HLA Protein Technologies Email Format

Biotechnology ResearchOklahoma, United States2-10 Employees

HLA Protein Technologies focuses on producing soluble HLA proteins derived from mammalian expression systems, preserving native-like structure and peptide occupancy for research and therapeutic applications. The company supports researchers with validated Class I and II HLA molecules and a range of services, including quantitative peptide binding analysis, T-cell epitope mapping, immune target validation, and transplant antibody monitoring assay development. Its customer base includes academic laboratories, transplant centers, CROs, and biopharma teams operating in oncology, vaccines, transplantation, and translational immunology.

The product portfolio comprises 126 Class I and 154 Class II HLA molecules in unmodified and biotinylated formats, backed by lot-traceable QC and standardized SOPs to ease assay transfer. The business is based in Oklahoma City, Oklahoma, and operates with a small team. In late 2025, the firm announced the commercial launch of a soluble HLA-G product portfolio.

Sign up for free to view info

Company overview Employee directory